The Center for Medicare and Medicaid Services’ approach to choosing competitors that serve as pricing benchmarks for the drugs selected for the Medicare negotiation program will probably be easier to predict as the program matures, according to CMS senior advisor Kristi Martin.
Medicare Negotiation: Therapeutic Alternatives Selection Will Become More Predictable, CMS Says
The selection process timeline will not change, but as the Medicare price negotiation matures, industry will better understand how therapeutic alternatives are chosen to inform the process, according to an official with the Centers for Medicare and Medicaid Services.
More from Market Access
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
A former CMS manager worries casework and other necessary functions could suffer as a result of the 300 staff cuts at the agency that are part of a massive HHS restructuring.